Introduction. Abstract. Akira Kikuchi, Ryoji Hanada Division of Hematology / Oncology, Saitama Children s Medical Center
|
|
- Martha Daniels
- 7 years ago
- Views:
Transcription
1 Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse after Initial Allogeneic Transplant in Childhood Leukemia - A Single Center Experience Akira Kikuchi, Ryoji Hanada Division of Hematology / Oncology, Saitama Children s Medical Center Abstract To evaluate the efficacy of second allogeneic hematopoietic stem cell transplantation (HSCT) for relapse after initial allogeneic transplant in childhood leukemia, we reviewed twenty-one patients who received second allogeneic HSCT for recurrent acute lymphoblastic leukemia (n=14), acute myelogenous leukemia (n=6) or chronic myelogenous leukemia (n=1). Of twenty-one patients, seven patients survived after the second HSCT with a median time of 16 months (range 2-95). Among several clinical characteristics, complete remission or chronic phase at the second HSCT showed a significant impact on better survival (46.9 +/ % versus 0%, p=0.0012). Although the outcome might be dismal especially in the patients who received second HSCT while in non-remission status, if remission of relapse is obtained after initial HSCT, a second HSCT should be considered as a curative treatment strategy for these patients. Keywords: childhood leukemia, second transplant, disease status at transplant Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative treatment for children with hematological malignancies refractory to or relapsing after conventional chemotherapy although more than 80% of childhood leukemia patients can be cured only by modern chemotherapy. 1 However, patients experiencing relapse after HSCT have a very poor prognosis and an optimal salvage therapy has yet to be established. Current treatment options include chemotherapy, donor leukocyte infusion (DLI) 2 and second HSCT Intensive chemotherapeutic regimens can induce remission in some patients with recurrent leukemia, but remission durations are short, and most patients die of uncontrolled leukemia or infectious complications. Although DLI results in durable clinical and molecular remission in chronic myelogenous leukemia (CML), results of DLI for acute leukemia are less encouraging. 2 Second allogeneic transplantation may be effective salvage therapy in some patients who relapse after an initial transplant. To date, most studies Correspondence to: Akira Kikuchi MD, PhD, Division of Hematology/Oncology, Saitama Children s Medical Center, 2100 Magome Iwatsuki-ku, Saitama-shi Saitama , Japan. Tel: , Fax: , a @pref.saitama.lg.jp 99
2 Akira Kikuchi of second transplants for recurrent leukemia are limited in adult patients and there are no reports on second HSCT in childhood leukemia. In this article, we analyzed results of second HSCT for leukemia relapse after initial transplants at our center. Patients and methods Between May 1992 and June 2008 at Saitama Children s Medical Center, twenty-one patients received second allogeneic HSCT for recurrent acute lymphoblastic leukemia (ALL; n=14), acute myelogenous leukemia (AML; n=6) or CML (n=1). Clinical characteristics of these patients prior to the first and the second HSCT are described in Table 1. Median patient age at HSCT was 5 years (range 0-16). Median time from first HSCT to relapse was 5 months (range 3-60), median time from relapse to second HSCT was 6 months (range 1-22 ) and median interval between first and second HSCT was 13 months (range 3-62 ).0Several clinical characteristics were compared between surviving and non-surviving patients. Survival curves were calculated by the Kaplan- Meier method 12 and differences of survival curves were evaluated by log rank test. Results Stem cell source Treatment and clinical outcomes of the second HSCT are shown in Table 1. Stem cell sources for the second Table 1. Patient characteristics and outcomes UPN Age/Sex Diagnosis Donor for HSCT1 to HSCT1 to Disease acute Survival Cause of HSCT status GVHD death HSCT1 HSCT2 Relapse HSCT2 at HSCT2 HSCT1 HSCT2 after HSCT2 1 3/M ALL MSD-BM MSD-BM 3 6 RL DOD 2 1/M ALL R- BM R- PB 5 13 RL DOD 3 3/M ALL U- BM U- CB 5 9 RL DOD 4 6/F ALL U- BM U- BM RL 2 NE 1 DOD 5 16/M ALL MSD-PB MSD-PB 8 11 CR DOD 6 0/M ALL U- CB U- CB CR NA 7 11/F ALL R- BM R- PB 3 4 RL DOD 8 1/M ALL U- CB U- BM 3 14 CR BO 9 4/M ALL U- BM U- BM 7 13 CR DOD 10 11/F ALL R- PB R- PB 3 7 RL MOF 11 0/F ALL U- CB U- BM 9 46 CR NA 12 0/M ALL U- CB U- BM 7 12 CR NA 13 2/F ALL U- BM U- BM 5 13 CR NA 14 8/M ALL U- BM U- BM 5 16 CR NA 15 10/F AML MSD-BM MSD-PB 3 25 CR DOD 16 6/M AML R- BM R-PB RL DOD 17 6/M AML U- BM R-PB RL MOF 18 8/F AML R- BM MSD-BM CR NA 19 14/F AML U- BM R- PB 3 5 RL GVHD 20 3/M AML U- CB U- BM 3 11 RL DOD 21 5/F CML MSD-BM MSD-PB CP NA Abbreviations: MSD = matched sibling donor; BM = bone marrow; R = related; U = unrelated; PB = peripheral blood stem cell; CB = cord blood; RL=relapse; CR= complete remission; CP= chronic phase; DOD = died of disease; BO= bronchiolitis obliterans; MOF = multiple organ failure; GVHD = graft versus host disease; NE= not evaluable; NA = not applicable. * Age is indicated in years. All periods are indicated in months. Plus sign indicates the patient is still alive. 100
3 Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse... HSCT were BM in 10 (MSD=2, Unrelated=8), PB in 9 (MSD=3, Related other than MSD=6) and CB in 2 (Unrelated=2). Conditioning Regimen HSCT. The For the first Experience HSCT, sixteen patients of underwent Caring total for a Person with a Mental body irradiation (TBI). The remaining five patients received busulfan(bu). Five patients, who Illness: received BU A Survival Grounded Theory Study for the first HSCT, received TBI for the second HSCT. Reduced intensity conditioning (nontbi, nonbu) was used for four patients for the second HSCT. Engraftment One patient died before engraftment was evaluable. For the remaining twenty patients, engraftment was prompt and durable. There was no late graft failure. Graft versus host disease Among twenty evaluable patients, thirteen patients developed acute GVHD, with nine having grade 2-4 disease. Fourteen patients developed acute GVHD after their first HSCT. Nine of these fourteen patients also had acute GVHD after their second HSCT. Conversely, among seven patients with no acute GVHD after the first HSCT, four developed acute GVHD after the second Of twenty-one patients, seven patients survived after the second HSCT with a median follow-up of 16 months (range 2-95). The cause of death was relapse in 10, MOF in 2, BO in 1 and GVHD in 1. Overall survival rate after the second HSCT was calculated as / %. We compared several characteristics between survivors and non-survivors. Among clinical characteristics such as remission duration after the first HSCT, stem cell source for the second HSCT, disease status at the second HSCT, conditioning regimen for the second HSCT or GVHD after the second HSCT, complete remission or chronic phase at the second HSCT showed a significant impact on better survival as shown in Fig.1 (remission or chronic phase versus non-remission: / Fig. 1. Survival curves after the second HSCT according to the disease status. Patients in complete remission or chronic phase at the second HSCT showed a better survival rate. Austral - Asian Journal of Cancer ISSN , Vol. 9, No. 2, April 2010 pp
4 Akira Kikuchi % versus 0 %, p=0.0012). Remission duration of more than 12 months after the first HSCT showed marginal significance (more than 12 months versus 12 month or less: / % versus / %, p=0.119). Stem cell source for the second HSCT, conditioning regimen for the second HSCT or GVHD after the second HSCT did not show any significant impact on better survival (data not shown). Discussion The use of dose-intensive chemotherapy regimens followed by allogeneic HSCT is an established curative treatment for patients with hematological malignancies refractory to or relapsing after conventional chemotherapy. However, patients experiencing relapse after HSCT have a very poor prognosis. Currently, the best curative option for these patients is second allogeneic HSCT. To date, most studies of second transplants for recurrent leukemia have been limited in adult patients and there are no reports on second HSCT in childhood leukemia. In this article, we report the outcome of twenty-one patients who received second HSCT for leukemia relapse after initial transplants at our center. The overall survival rate of these patients was / %. This figure is obviously low compared with the survival rate after the first line HSCT for childhood leukemia. The cause of death in fourteen died patients was relapse in 10, MOF in 2, BO in 1 and GVHD in 1. Considering the high rate of relapse as the cause of death among these patients, the most important factor for successful second HSCT is good control of primary disease. Compared with HSCT in adults, transplantation mortality rate is relatively low in childhood HSCT, therefore uncontrollable primary disease is the most serious problem. In fact, among the remaining four patients who died, three patients had received allogeneic peripheral blood stem cell transplantation from HLApartially mismatched parents at non-remission status. Although they died of transplantation related toxicity, such poor HSCT conditions might have influenced these outcomes. Several prognostic factors have been reported to predict the outcome of second HSCT. Among several clinical characteristics such as remission duration after the first HSCT, 6, 10, 11 stem cell source for the second HSCT, 10 disease status at the second HSCT, 10 conditioning regimen for the second HSCT 10 or GVHD after the second HSCT, 3 only complete remission or chronic phase at the second HSCT showed a significant impact on better survival (Fig.1). Again, the importance of primary disease control was reconfirmed. Indeed, all of the ten patients who received second HSCT while in a non-remission status died; in particular, seven of these ten died within 8 months after HSCT. For patients whose disease does not respond to remission induction therapy for relapse after initial HSCT, a quite novel treatment strategy is needed. Otherwise, palliative therapy might be indicated to preserve the quality of life for these patients. However, the survival rate of patients who received the second HSCT while in complete remission or chronic phase was / % although some patients still have a short observation period. We think this survival rate is very encouraging and comparable with adult data If remission is obtained for relapse after initial HSCT, the second HSCT should be considered as a curative treatment strategy for these patients. We could not evaluate the significance of stem cell source or conditioning regimen because of the heterogeneity in this retrospective analysis. Evaluation of the significance of stem cell source is difficult because of the limitation of allogeneic donor availability. To evaluate the significance of conditioning regimen, a uniform conditioning regimen designed especially for second HSCT will be required. 11 One patient, who received the second HSCT during second complete remission, died of BO. This is the only patient who died while in remission. Because receiving full dose HSCT twice can induce serious complications in some patients, reduced intensity HSCT might be indicated for selected patients in remission as reported in adult patients. 9,11 In this article, we reported twenty-one patients who received second allogeneic HSCT for relapse after initial allogeneic transplant in childhood leukemia at our center. The outcome might be dismal especially in patients who received second HSCT while in a nonremission status, however, the outcomes of patients who received second HSCT during remission was encouraging. Further study is needed to establish a safe and efficient treatment strategy for relapse after initial allogeneic transplant in childhood leukemia. References 1 Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2006; 350: Collins RH, Shpilberg O, Drobyski WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: Mrsic M, Horowitz MM, Atkinson K et al.: Second HLA-identical 102
5 Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse... sibling transplants for leukemia recurrence. Bone Marrow Transplantation 1992; 9: Radich JP, Sanders JE, Buckner CD et al.: Second marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11 : Kumar L: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994;7: Chiang KY, Weisdorf DJ, Davies SM et al.: Outcome of second bone marrow transplantation following a uniform conditioning regimen as a therapy for malignant relapse. Bone Marrow Transplant 1996;17: Basara N, Bischoff M, Blau IW et al. A second unrelated bone marrow transplant with an unrelated donor marrow: treatment of a patient with relapsed leukemia. Bone Marrow Transplant 1998;21: Bosi A, Laszlo D, Labopin M et al.: Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European cooperative group blood and marrow transplantation. J Clin Oncol 2001;9: Fernstein LC, Sandmaier BM, Maloney DG et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003;9: Eapen M, Giralt SA, Horowitz MM et al.: Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: Grullich C, Bertz H, Spyridonidis A et al.: A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second hematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant 2008; 41: Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:
Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationSibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program
Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationOutcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)
Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationGraft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationHematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD
Hematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD Stem cell transplantation Autologous Autologous stem cell collection Freeze Stem Cells
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationNavelstrengbloed tegen kanker
Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and
More informationMyeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants
Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationstorage and handling of unused stem cell products Swiss consensus?
storage and handling of unused stem cell products Swiss consensus? 16. Jan. 2015 Panagiotis Samaras, Mario Bargetzi stored units USZ Type of unused product autologous stem cells never transplanted 2nd
More informationWBMT Global Survey. Helen Baldomero Cape Town November 2014. Worldwide Network for Blood and Marrow Transplantation
WBMT Global Survey Helen Baldomero Cape Town November 214 NGO in official relations with World Health Organization Leukemias LPD Solid tumors Non - Malignant disorders NGO in official relations with World
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationMyeloablative conditioning regimens for the
ACUTE MYELOID LEUKEMIA What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Stephen J. Forman 1 1 Department of Hematology and Hematopoietic Cell Transplantation,
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationOUR JOURNEY THROUGH THE YEARS
The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist
More informationHaematopoietic stem cell transplantation in Hong Kong
S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationSTUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan
STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly
More informationSESUG 2011 INTRODUCTION. Paper GH-12
Paper GH-12 Development of a SAS Macro for Automated Data Cleaning of Major Outcomes of Interest in Hematopoietic Cell Transplantation Peigang Li, Min Chen and Zhiwei Wang, CIBMTR, Milwaukee, WI ABSTRACT
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationStem Cell Transplantation in Severe Aplastic Anemia
Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More informationUmbilical Cord Blood Transplantation for the Treatment of Hematologic Malignancies
Umbilical cord blood transplantation is a useful treatment in several types of hematologic malignancies. Gene Elling. St. Lucia. Photograph. Umbilical Cord Blood Transplantation for the Treatment of Hematologic
More informationEBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 CHAPTER 20. HSCT for acute myeloid leukaemia in adults. R. Varaldo, F. Frassoni
EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 * CHAPTER 20 HSCT for acute myeloid leukaemia in adults R. Varaldo, F. Frassoni EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 357 CHAPTER 20 AML in adults
More informationStem Cell Transplantation in Adults
Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More informationCord Blood Biology and Transplantation
Cord Blood Biology and Transplantation Yossi Cohen MD MSc and Arnon Nagler MD Institute of Hematology, Department of Bone Marrow Transplantation and Cord Blood Bank, Sheba Medical Center, Tel Hashomer,
More informationObjectives. Cord Blood. Case 1. Case 1. Case 1. Case 1. To provide a framework for answering a family s questions about cord blood storage.
Cord Blood Should we save the baby s cord blood? Meghan A. Higman, MD, PhD Clinical Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology Assistant Professor of Oncology Pediatrics
More informationNot for publication or presentation
MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: 301-402-4899;
More informationUmbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation
Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Mary J. Laughlin, MD Associate Professor of Medicine and Pathology Dr. Donald and Ruth Weber Goodman Professor of Innovative
More informationHow To Transplant Cord Blood
MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationClinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April 2013. Reference: NHSCB/B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation First published:
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014 The ideal HSCs source Immediate availability Few HLA restrictions
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationSection: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015
Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:
More informationDouble cord blood transplantation
DCTH - 2 2013-113-121 REVIEW Double cord blood transplantation R. Angarano, I. Donnini, B. Bartolozzi, A. Bosi Ematologia, Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Italy SUMMARY
More informationStammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del
Allogene Neues vom immunologischen Ctrl-Alt-Del Prof. Dr. med. Wolfgang Bethge Allogene am ASH Insgesamt 715 Abstracts zum Thema Auswahl: Azacitidine als Überbrückung zu allogenen SZT bei MDS Ergebnis
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationHematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia
Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia Policy Number: Original Effective Date: MM.07.026 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/26/2013 Section:
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationThe Value of Cord Blood Stem Cells. Mona Shafey, MD, FRCPC Medical Grand Rounds October 25 th, 2011
The Value of Cord Blood Stem Cells Mona Shafey, MD, FRCPC Medical Grand Rounds October 25 th, 2011 Objectives To discuss umbilical cord blood as a stem cell source and the role of umbilical cord blood
More informationCord Blood Transplant Past and Future. E. Gluckman Eurocord ISCT Paris 24/04/2014
Cord Blood Transplant Past and Future E. Gluckman Eurocord ISCT Paris 24/04/2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationBlood and Marrow Stem Cell Transplantation
Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to
More informationHematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:
More informationUmbilical cord blood transplantation
Review article http://dx.doi.org/10.3345/kjp.2012.55.7.219 Korean J Pediatr 2012;55(7):219-223 eissn 1738-1061 pissn 2092-7258 Umbilical cord blood transplantation Hong Hoe Koo, MD 1, Hyo Seop Ahn, MD
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationHematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes
Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia
More informationIn a number of genetic, hematologic, and oncologic
AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationUMBILICAL CORD BLOOD STATISTICS
UMBILICAL CORD BLOOD STATISTICS INTRODUCTION Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace
More informationProtocol. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia
Hematopoietic Stem Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 04/01/13 Next Review Date: 03/16 Preauthorization Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12,
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationData Reporting Problems
Data Reporting Problems Shelley Hewerdine & Khrystyna Valkiv Istanbul, 23rd March 2015 #EBMT2015 www.ebmt.org Format of this session Recent EBMT Registry work Improving Data Quality Data reporting Quiz
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationDESCRIPTION/BACKGROUND
Original Issue Date (Created): August 23, 2004 Most Recent Review Date (Revised): Effective Date: October 21, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND Hematopoietic Stem-Cell Transplantation
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationCord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD
Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer
More informationClinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies
Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies KOICHIRO KOBAYASHI 1, YOSHINOBU MAEDA 1, YOSHITAKA HARA 1, MIYUKI NISHIE-KATAOKA
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 118 No 1208 ISSN 1175 8716 Private umbilical cord blood banking: a biological insurance of dubious future benefit! Michael Sullivan, Peter Browett, Nigel Patton In its
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More information